BIOAGE Labs

BIOA · NASDAQ

$5.56+$0.57 (+11.42%)TodayMarket closed · Oct 20, 7:31 PM ET

Prev close $4.99

BIOA analyst rating

BuyConsensus of 9 analysts over the last 12 months. 78% rate it a buy.

Strong buy0
Buy7
Hold2
Underperform0
Sell0

12-month price target · 10 analysts

Average $36.34 (+553.6% upside)

Low: $20.20
Now: $5.56
High: $76.65

Upgrades and downgrades

The latest rating actions, newest first

BIOA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 12, 2026	Initiates	Neutral	$8.00	0%
Roth Capital	Sep 9, 2026	Maintains	Buy	$25.00	17%
BTIG	Sep 8, 2026	Maintains	Buy	$40.00	30%
BTIG	Aug 6, 2026	Maintains	Buy	$40.00	30%
BTIG	Aug 3, 2026	Maintains	Buy	$40.00	30%
Needham	Jul 31, 2026	Maintains	Buy	$50.00 → $35.00	47%
Roth Capital	May 27, 2026	Initiates	Buy	$36.00	17%
BTIG	May 13, 2026	Initiates	Buy	$40.00	30%
Needham	Mar 27, 2026	Initiates	Buy	$50.00	47%
Citigroup	Mar 10, 2026	Maintains	Buy	$15.00 → $52.00	36%

The case for and against

Updated Oct 16, 2026

Bull case

Bioage Labs is favorably positioned because its lead asset BGE-102 combines an orally bioavailable, brain-penetrant NLRP3 inhibitor with a proprietary human-aging dataset and rigorous translational science, giving it a differentiated approach to aging and chronic inflammation. The company’s early data showing roughly 90% IL1b reduction and 80% to 90% hs-CRP suppression support a biologically meaningful anti-inflammatory effect, while the mechanism sits upstream of IL1b and IL6, potentially offering broader cardiovascular and ocular benefits than narrower complement-focused strategies. With a four-year cash runway, first participant dosing in the QUELL-CV P2 trial, topline data anticipated in 2H26, and BGE-105 advancing toward mid-27, the pipeline has multiple value-creating catalysts without near-term balance sheet pressure.

Bear case

Bioage Labs is viewed negatively because its valuation is highly exposed to clinical, regulatory, financing, and intellectual-property risks, with BGE-102 composition-of-matter patents only running to 2045 and any successful challenge or early generic entry likely to compress value materially. The company had $381.3 million of cash, equivalents, and marketable securities at June 30, 2026, but still faces potential dilution from a modeled $200 million gross raise in FY27E and another $215 million in FY31E, even with runway guided through 2029. Fundamentally, the investment case is weakened by mixed data: next trials support safety and hsCRP reduction, yet synergy with weight-loss drugs is modest, ZEUS was a surprise, and the clinical relevance of hs-CRP appears less certain than hoped.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.